Could your own cells replace daily anti-rejection pills after a kidney transplant?
NCT ID NCT06777719
First seen May 10, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This early-phase study tests whether a patient's own immune cells, called CD8+ regulatory T cells, can be grown in a lab and then given back to them after a kidney transplant. The goal is to see if this cell therapy is safe and might allow patients to take fewer standard anti-rejection drugs. Nine adults receiving a kidney from a living donor will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nantes
RECRUITINGNantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.